Fig. 6From: The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritisAcute phase response parameters in a cynomolgus monkey model of inflammation. Effect of a single dose of ALX-0061 (0.4, 2, or 10 mg/kg) on different acute phase response parameters is shown. (a) C-reactive protein plasma levels. (b) Fibrinogen plasma levels. (c) Platelet counts. Data were processed as follows: group mean values were calculated, error bars represent SEM, and platelets concentrations were normalized relative to individual baseline levels to reduce the inter-animal variation. CRP: C-reactive protein; SEM: standard error of meanBack to article page